Instead, inhibiting the interaction of ERK1/2 with GABAB receptors using interfering peptides might be a promising, highly specific approach for the development of a neuroprotective treatment in cerebral ischemia or other neurological diseases associated with neuronal overexcitation and downregulation of GABAB receptors. Here, MAPK3 is linked to brain ischemia.